Drug Profile


Alternative Names: Alzumab; Anti-CD6 monoclonal antibody - Biocon/CIMAB; Anti-CD6 monoclonal antibody h-T1; h T1; Humanised anti-CD6 monoclonal antibody ior t1; T12 antibody; T12 monoclonal antibody; T1h; T1hT

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Biocon; Biotech Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action CD6 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Phase II Rheumatoid arthritis
  • Phase I Autoimmune disorders
  • No development reported Multiple sclerosis; Psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Psoriasis(Treatment-experienced) in China (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in India (Parenteral)
  • 29 Aug 2016 Biocon plans a phase I/II trial for Multiple sclerosis in Cuba (RPCEC00000197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top